Pancreatic Neoplasms clinical trials

The registry lists 3,896 studies for Pancreatic Neoplasms across more than 10 countries. 1,006 are recruiting or about to start. 2,769 of them are mainly about Pancreatic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 11 narrower conditions too, such as Adenoma, Islet Cell: 4,169 studies, 1,080 open.

ClinicalTrials.gov finds 5,126 studies for Pancreatic Neoplasms. How that becomes 3,891 here

This page counts the studies the registry files under Pancreatic Neoplasms, and those it files under no condition that list Pancreatic Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

5,126Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−223Filed under a narrower condition, counted on its own pageAdenoma, Islet Cell 93 · Insulinoma 38 · Carcinoma, Pancreatic Ductal 32 · Pancreatic Intraductal Neoplasms 18 · Somatostatinoma 15 · Pancreatic cancer, adult 8 · 4 more
−57List Pancreatic Neoplasms as a condition, but the registry did not file them under itMost often written as “Pancreatic Cancer Resectable” (9), “Pancreatic Cancer Metastatic” (8), and “Pancreatic Cancer Non-resectable” (7). The registry filed them under other conditions only, most often Colorectal Neoplasms (9) and Neoplasms (8).
−955Match it another way282 name it in the title, 9 in a keyword, and 664 by a synonym or other text the search reads.
3,891The count on this page212 of them list Pancreatic Neoplasms in their own words; the registry filed them under no condition.

Get an email when these change. Save the Pancreatic Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,564
Recruiting: 745
Status unknown: 464
Terminated: 407
Active, not recruiting: 269
Not yet recruiting: 234

Phase

Phase 2: 1,354
Phase 1: 1,103
Phase 3: 237
Early Phase 1: 92
Phase 4: 51

Where

United States: 1,852
China: 629
France: 234
Italy: 214
Spain: 202
Korea, Republic of: 198

Who runs them

National Cancer Institute (NCI) (114) · M.D. Anderson Cancer Center (66) · Fudan University (54) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (52) · Memorial Sloan Kettering Cancer Center (50) · Mayo Clinic (40) · Washington University School of Medicine (34) · Changhai Hospital (34)

What is being tested here

Drugs under test in Pancreatic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Gemcitabine	24	34	349
Paclitaxel	19	7	116
Albumin-Bound Paclitaxel	19	7	107
Irinotecan	13	10	64
Adebrelimab	11	0	11
KRAS G12D Inhibitor HRS-4642	9	0	9
Irinotecan sucrosofate	8	2	19
Oxaliplatin	7	15	79
Fluorouracil	7	14	75
Daraxonrasib	7	4	8

Drug classes tested here Immune checkpoint inhibitors 56 open · Antimetabolites 38 open · Antimitotic agents 23 open · Tyrosine kinase inhibitors (TKIs) 20 open · PARP inhibitors 7 open

Coming up

74phase 3 studies under way

374studies finish main data collection within a year15 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer · Phase 3 · Fudan University
Dec 2026Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer · Phase 3 · GC Cell Corporation
Dec 2026Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer · Phase 3 · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Dec 2026Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? · Phase 3 · Case Comprehensive Cancer Center
Jan 2027Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer · Phase 3 · Erasmus Medical Center
Mar 2027HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer · Phase 3 · Fudan University
May 2027A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer · Phase 3 · Akeso
May 2027Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer · Phase 3 · Tianjin Medical University Cancer Institute and Hospital
May 2027Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy · Phase 3 · Evopoint Biosciences Inc.
Jun 2027A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer · Phase 3 · Lepu Biopharma Co., Ltd.

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger. 40 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 59 (8%) take healthy volunteers.

Recruiting studies that take each age, of 745
Age	Women	Men
10	29 (4%)	29 (4%)
18	691 (93%)	691 (93%)
30	726 (97%)	726 (97%)
40	733 (98%)	733 (98%)
50	741 (99%)	741 (99%)
65	743 (100%)	743 (100%)
75	719 (97%)	719 (97%)
85	535 (72%)	535 (72%)

Across all 3,896 studies, recruiting or not: 14% stop at 75 or younger and 1% at 65; 5% take children; <1% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pancreatic Neoplasms studies take

Of 393 phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 57 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	45 mo32–67 · 379 studies	44 mo31–62 · 171 studies	46 mo33–74 · 208 studies
Phase 1/2	51 mo36–89 · 209 studies	47 mo34–88 · 115 studies	61 mo38–95 · 94 studies
Phase 2	57 mo35–80 · 393 studies	36 mo26–68 · 69 studies	60 mo36–80 · 324 studies
Phase 3	58 mo36–77 · 84 studies	—	68 mo39–79 · 46 studies
Interventional, no phase	44 mo26–75 · 430 studies	—	45 mo26–75 · 403 studies
Observational	60 mo34–182 · 352 studies	—	74 mo34–182 · 318 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out